
-
Olema Pharmaceuticals NasdaqGS:OLMA Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors palbociclib and ribociclib, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, and with an mTOR inhibitor everolimus that is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer. It also develops OP-3136, an orally-available small molecule that potently and selectively inhibits KAT6 for patients with ER+/HER2- metastatic breast cancer and other cancers which is in Phase 1 clinical trial. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Location: 780 Brannan Street, San Francisco, CA, 94103, United States | Website: https://olema.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-69.29M
Cash
392.7M
Avg Qtr Burn
-31.21M
Short % of Float
13.79%
Insider Ownership
3.32%
Institutional Own.
98.86%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
OP-1250 (palazestrant) (CER antagonist) Details Metastatic breast cancer, Cancer | Phase 3 Data readout | |
Palazestrant (OP-1250) + ribociclib Details ER+/HER2- breast cancer, Cancer | Phase 3 Initiation | |
OP-1250 (palazestrant) + everolimus Details Metastatic breast cancer, Breast cancer, Cancer | Phase 1/2 Data readout | |
OP-1250 (palazestrant) +palbociclib Details Metastatic breast cancer, Breast cancer, Cancer | Phase 1/2 Update | |
OP-1250 (palazestrant) + ribociclib or alpelisib Details Breast cancer, Metastatic breast cancer, Cancer | Phase 1/2 Update | |
OP-3136 Details Cancer, ER+/HER2- breast cancer | Phase 1 Data readout |